Results 221 to 230 of about 3,292,689 (405)

Activation of the Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor System in Periodontitis: A Case–Control Study

open access: yesInternational Journal of Dental Hygiene, EarlyView.
ABSTRACT Introduction The plasminogen activating (PA) system has a multitude of functions such as wound healing, proteolytic activity, collagen degradation and cell growth, and the role of the urokinase plasminogen activator/urokinase plasminogen activator receptor (uPA/uPAR) system has been studied in many disease states.
Ahmed Khudhur   +6 more
wiley   +1 more source

SUN-LB047 Two Unusual Cases of Pituitary Tumors Presenting with Acromegaly

open access: gold, 2019
Shilpa Gurnurkar   +2 more
openalex   +1 more source

Dermatologic Features of Endocrine Tumor Syndromes—Systematic Review and Meta‐Analysis

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Endocrine tumor syndromes, including multiple endocrine neoplasia types 1, 2A, and 2B (MEN1, MEN2A, MEN2B), Carney complex (CNC), and PTEN hamartoma tumor syndrome (PHTS), are hereditary conditions characterized by multisystem tumor development.
Sára Pálla   +8 more
wiley   +1 more source

Hypersscretion of ACTH growth hormone and prolactin in a patient with pituitary adenoma [PDF]

open access: yes, 1978
Fink, R.   +3 more
core   +1 more source

MALDI mass spectrometry imaging analysis of pituitary adenomas for near-real-time tumor delineation

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2015
David Calligaris   +10 more
semanticscholar   +1 more source

Safety of anagliptin/metformin combination tablets evaluated by non‐inferiority between pre‐ and post‐serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment (AMELIO STUDY)

open access: yesJournal of Diabetes Investigation, EarlyView.
To investigate the safety of anagliptin/metformin combination tablets in Japanese patients of type 2 diabetes with moderate renal impairment. This study demonstrates that the fixed‐dose combination of anagliptin and metformin can be used safely in patients with type 2 diabetes complicated by moderate renal dysfunction.
Hiroshi Kajio   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy